- Home
- FBGL vs MYNZ Comparison
FBGL vs MYNZ Comparison
Compare FBGL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBGL
- MYNZ
- Stock Information
- Founded
- FBGL 1996
- MYNZ 2021
- Country
- FBGL Singapore
- MYNZ Germany
- Employees
- FBGL N/A
- MYNZ N/A
- Industry
- FBGL Miscellaneous manufacturing industries
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- FBGL Consumer Discretionary
- MYNZ Health Care
- Exchange
- FBGL Nasdaq
- MYNZ Nasdaq
- Market Cap
- FBGL 8.1M
- MYNZ 7.0M
- IPO Year
- FBGL 2025
- MYNZ 2021
- Fundamental
- Price
- FBGL $0.62
- MYNZ $2.27
- Analyst Decision
- FBGL
- MYNZ Buy
- Analyst Count
- FBGL 0
- MYNZ 2
- Target Price
- FBGL N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- FBGL 360.1K
- MYNZ 303.1K
- Earning Date
- FBGL 01-01-0001
- MYNZ 05-27-2025
- Dividend Yield
- FBGL N/A
- MYNZ N/A
- EPS Growth
- FBGL N/A
- MYNZ N/A
- EPS
- FBGL 0.04
- MYNZ N/A
- Revenue
- FBGL $15,607,369.00
- MYNZ $893,991.00
- Revenue This Year
- FBGL N/A
- MYNZ $42.95
- Revenue Next Year
- FBGL N/A
- MYNZ N/A
- P/E Ratio
- FBGL $18.50
- MYNZ N/A
- Revenue Growth
- FBGL 25.78
- MYNZ N/A
- 52 Week Low
- FBGL $0.44
- MYNZ $0.18
- 52 Week High
- FBGL $5.45
- MYNZ $8.20
- Technical
- Relative Strength Index (RSI)
- FBGL N/A
- MYNZ 31.65
- Support Level
- FBGL N/A
- MYNZ $2.30
- Resistance Level
- FBGL N/A
- MYNZ $2.57
- Average True Range (ATR)
- FBGL 0.00
- MYNZ 0.36
- MACD
- FBGL 0.00
- MYNZ -0.03
- Stochastic Oscillator
- FBGL 0.00
- MYNZ 4.00
About FBGL FBS Global Limited Ordinary Shares
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial and industrial building projects. As a green contractor focused on environmentally sound practices, It aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, lead lining, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts, sales of construction materials, and rendering of services.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.